These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23403634)

  • 1. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
    Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
    Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
    Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
    Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
    Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
    Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
    Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
    Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
    Liu H; Liao R; He K; Zhu X; Li P; Gong J
    Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
    Srivastava AK; Jaganathan S; Stephen L; Hollingshead MG; Layhee A; Damour E; Govindharajulu JP; Donohue J; Esposito D; Mapes JP; Kinders RJ; Takebe N; Tomaszewski JE; Kummar S; Doroshow JH; Parchment RE
    Clin Cancer Res; 2016 Feb; 22(4):1000-10. PubMed ID: 26446940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
    Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
    Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme.
    Cerna D; Lim B; Adelabu Y; Yoo S; Carter D; Fahim A; Mitsuuchi Y; Teicher BA; Bernhard E; Coleman CN; Takebe N; Ahmed MM
    Radiat Res; 2021 Jun; 195(6):549-560. PubMed ID: 33826739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
    McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
    Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
    Vetma V; Rožanc J; Charles EM; Hellwig CT; Alexopoulos LG; Rehm M
    Oncol Res; 2017 Nov; 25(9):1489-1494. PubMed ID: 28337955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
    Condon SM; Mitsuuchi Y; Deng Y; LaPorte MG; Rippin SR; Haimowitz T; Alexander MD; Kumar PT; Hendi MS; Lee YH; Benetatos CA; Yu G; Kapoor GS; Neiman E; Seipel ME; Burns JM; Graham MA; McKinlay MA; Li X; Wang J; Shi Y; Feltham R; Bettjeman B; Cumming MH; Vince JE; Khan N; Silke J; Day CL; Chunduru SK
    J Med Chem; 2014 May; 57(9):3666-77. PubMed ID: 24684347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.